drugset / Trial / NCT01336920
Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma
Phase 1
Completed
15 enrolled
University of Nebraska
Amgen · collabNational Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase I trial studies the side effects and best dose of carfilzomib in treating patients with relapsed or refractory T-cell lymphoma. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Timeline
- Start
- 2011-06-21
- Primary completion
- 2015-04-01
- Completion
- 2018-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carfilzomib | Other / unclassified | — | Intravenous |